Urania Pharmaceuticals Q3 2026: Revenue Surge, Lupe Therapy Drives Growth & Strong Cash PositionDiscover Aurinia Pharmaceuticals’ Q3 2026 earnings: revenue up, LUPKYNIS sales surge, new product launch, and stronger cash position.AURINIA PHARMACEUTICALS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 31/10/2026, 04:21 2 minutes to read